Biogen Idec presents pooled Phase III safety and efficacy data for MS drug
This article was originally published in Scrip
Executive Summary
As it awaits worldwide approval for its oral multiple sclerosis treatment, BG-12 (dimethyl fumarate), Biogen Idec has been providing additional insight into the positive efficacy and safety results from Phase III studies of the drug.